

### **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

### **LISTING OF CLAIMS:**

Claims 1 to 16 (Canceled)

17. (New) A method of administering to a subject a chimeric parainfluenza virus comprising:

- (i) nucleotide sequences of a bovine parainfluenza virus type 3 genome; and
- (ii) one or more heterologous sequences, wherein said one or more heterologous sequences have been added to said virus genome or have been substituted for nucleotide sequences of said virus genome.

18. (new) The method of claim 17, wherein the heterologous sequences are that of a human parainfluenza virus.

19. (new) The method of claim 18, wherein the heterologous sequences encode the F and HN glycoproteins of a human parainfluenza virus.

20. (new) The method of claim 19, wherein the F and HN glycoproteins of an hPIV are that of a human parainfluenza virus type 3.

21. (new) The method of claim 17, wherein the heterologous sequences are that of an influenza virus or of a respiratory syncytial virus.

22. (new) The method of claim 17, wherein the Kansas-strain bPIV3 backbone contains mutations or modifications, in addition to heterologous sequences, which result in a chimeric virus having a phenotype more suitable for use in vaccine formulations such as an attenuated phenotype or a phenotype with enhanced antigenicity.

23. (new) A method of administering to a subject a chimeric parainfluenza virus comprising:

- (i) the genome of bovine parainfluenza virus type 3; and
- (ii) one or more heterologous sequences, wherein said one or more heterologous sequences have been added to said backbone.

24. (new) The method of any one of claims 17-23, wherein said heterologous sequence substitutes both the F and the HN gene of Kansas-strain bovine parainfluenza virus type 3.

25. (new) The method of any one of claims 17-23, wherein said heterologous sequence is added at a nucleotide position of Kansas-strain bovine parainfluenza virus type 3 selected from the group consisting of nucleotide position 5041, the HN gene, and nucleotide position 8529.

26. (new) The method of any one of claims 17-23 further comprising administering an adjuvant.

27. (new) The method of claim 26, wherein the adjuvant is a mineral gel, a surface active substance, a peptide, or an oil emulsion.

28. (new) The method of claim 27, wherein the adjuvant is aluminum hydroxide, lysolecithin, a pluronic polyol, a polyanion, BCG or *Corynebacterium parvum*.

29. (new) The method of any one of claims 17-23 wherein the chimeric parainfluenza virus is administered orally, intradermally, intramuscularly, intraperitoneally, subcutaneously, or intranasally.

30. (new) The method of claim 17 or 23, wherein the bovine parainfluenza virus type 3 is a Kansas-strain bovine parainfluenza virus type 3.